SCHEMBL28570313

SCHEMBL28570313

COCc1cc(Nc2cc(C)n[nH]2)nc(S(=O)(=O)c2ccc(C(=O)OC)cc2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ POLB P06746 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ GAA P10253 2/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ AURKA O14965 4/20 0.36
▸ METAP2 P50579 2/20 0.35
▸ MAPT P10636 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27598876 0.76 PARP1 (0.33) KMT2APOLBMEN1KDM4EHPGD
SCHEMBL28021626 0.76 ATM (0.46) KMT2APOLBMEN1RAB9AAURKA
SCHEMBL28021607 0.75 SLC2A1 (0.44) KMT2ASMN1; SMN2MEN1KDM4EHPGD
SCHEMBL28021678 0.73 ATM (0.45) KMT2AUSP2TSHRSMN1; SMN2POLB
SCHEMBL27598875 0.70 — —
SCHEMBL28021603 0.70 ALDH1A1 (0.42) KMT2AMEN1HPGDRXFP1RAB9A
SCHEMBL28022078 0.70 PKM (0.44) KMT2ATSHRPOLBMEN1KDM4E
SCHEMBL28549342 0.69 ACHE (0.48) KMT2ASMN1; SMN2POLBMEN1KDM4E
SCHEMBL2206867 0.69 MAPT (0.43) KMT2AMAPK1USP2TSHRSMN1; SMN2
SCHEMBL2205815 0.68 MAPT (0.43) KMT2APOLBMEN1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112755193-A Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof 德玛医药 2021-05-07 — — CN disclosed
CN-104797267-A Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof DEL MAR PHARMACEUTICALS 2015-07-22 — — CN disclosed
Send feedback